X‑Linked Dominant Retinitis Pigmentosa (XLD‑RP)

Overview

Retinitis pigmentosa (RP) refers to a heterogeneous group of inherited retinal dystrophies that cause progressive loss of photoreceptor cells. While most RP cases follow an autosomal‑dominant, autosomal‑recessive, or X‑linked recessive inheritance pattern, a rare form—X‑linked dominant retinitis pigmentosa (XLD‑RP)—has been documented in a handful of families worldwide. In this form, the disease‑causing gene is located on the X chromosome and a single copy of the mutant allele is sufficient to cause disease in both males and females, though severity often differs by sex.

Who it affects: Because the X chromosome is present in both males (XY) and females (XX), XLD‑RP can affect anyone, but males typically present earlier and with more severe visual loss. Females, who have a second, usually normal X‑chromosome, may experience milder symptoms that can appear later in life.

Prevalence: XLD‑RP is extremely rare—estimates range from 1 in 100,000 to 1 in 500,000 individuals worldwide. This rarity reflects both the scarcity of documented families and the likelihood that some cases are mis‑classified as other RP subtypes.

Sources: Mayo Clinic, National Eye Institute (NEI), Orphanet.

Symptoms

Symptoms develop slowly and can vary widely between individuals. The classic progression mirrors other RP forms, but some features are more prominent in XLD‑RP.

• Night blindness (nyctalopia): Difficulty seeing in low‑light conditions often appears in the first decade of life.
• Peripheral visual field loss: “Tunnel vision” gradually replaces peripheral sight as rod photoreceptors degenerate.
• Decreased color vision: Patients may notice that reds and blues appear faded.
• Photopsia: Occasional flashes of light or “sparkles” in the peripheral vision.
• Reduced visual acuity: Central vision can be preserved for many years, but later stages may involve macular involvement leading to blurred central vision.
• Fundus changes: On examination, clinicians may see bone‑spicule pigmentation, attenuation of retinal vessels, and optic disc pallor.
• Electroretinogram (ERG) abnormalities: Markedly reduced rod responses early on; cone responses decline later.
• Sex‑specific patterns:
  • Males: Earlier onset (often before age 10), rapid progression, early loss of night vision.
  • Females: Variable onset (teen‑to‑adult years) and milder field loss; some carriers remain asymptomatic.

Causes and Risk Factors

Unlike acquired retinal diseases, XLD‑RP is caused by a single pathogenic variant in a gene located on the X chromosome. The most commonly implicated genes include:

1. RP2 (Retinitis Pigmentosa 2): Mutations in RP2 account for ~10‑15 % of X‑linked RP and can behave in a dominant manner when the mutation exerts a gain‑of‑function effect.
2. OF D Gene (formerly RPGR‑ORF15): While RPGR mutations are classically X‑linked recessive, certain alleles act dominantly.
3. Other rare loci: Recent whole‑exome studies have identified additional X‑linked dominant candidates (e.g., C2orf71). Research is ongoing.

Inheritance pattern: An affected mother passes the mutant X chromosome to 50 % of her sons (who become affected) and 50 % of her daughters (who become carriers or affected depending on X‑inactivation). An affected father cannot transmit the disease to sons but will pass the mutant X to all daughters, who become carriers/affected.

Risk factors are primarily genetic:

• Having a parent (usually mother) with a confirmed XLD‑RP diagnosis.
• Family history of early‑onset night blindness or “tunnel vision.”
• Identified pathogenic variant on genetic testing.

Environmental factors (e.g., smoking, excessive sunlight) do not cause XLD‑RP but may influence the rate of progression, as discussed under “Complications.”

Diagnosis

Because early symptoms (night blindness) are nonspecific, a thorough diagnostic work‑up is essential.

Clinical Evaluation

• History: Detailed personal and family ophthalmic history, emphasizing age of symptom onset and inheritance clues.
• Visual field testing: Automated perimetry identifies peripheral field loss.
• Fundus examination: Ophthalmoscopy reveals the classic bone‑spicule pigmentary changes.

Functional Tests

• Electroretinography (ERG): Measures rod and cone activity; in XLD‑RP, rod responses are markedly reduced early.
• Multifocal ERG (mfERG): Helpful for assessing central macular function when visual acuity declines.

Imaging

• Optical Coherence Tomography (OCT): Shows thinning of the outer retinal layers and disruption of the ellipsoid zone.
• Fundus autofluorescence (FAF): Highlights areas of retinal pigment epithelium (RPE) stress before visible pigment changes.

Genetic Testing

Gene panels targeting known RP genes (including RP2 and RPGR) are the gold standard. Whole‑exome or whole‑genome sequencing can identify novel dominant X‑linked variants. Genetic counseling before and after testing is strongly recommended.

Diagnostic accuracy improves when clinical findings are combined with molecular results (≈90 % concordance in specialized centers).

Treatment Options

Currently, no cure exists for RP, but several interventions can slow progression, preserve vision, and improve quality of life.

Pharmacologic Therapies

• Vitamin A Palmitate (15,000 IU/day): Historically recommended for certain RP forms; however, its benefit in XLD‑RP is uncertain and it carries liver toxicity risk. Must be prescribed and monitored by an ophthalmologist or retinal specialist.
• Omega‑3 fatty acids (DHA/EPA): Some observational data suggest modest visual field preservation; consider as a dietary supplement after discussing with a clinician.
• Oral N‑acetylcysteine (NAC): Ongoing clinical trials (e.g., NCT03063021) are evaluating antioxidant effects on RP progression.

Gene‑Specific and Cell‑Based Approaches

• Gene augmentation therapy: Adeno‑associated viral (AAV) vectors delivering a functional RP2 copy are in Phase I/II trials (see ClinicalTrials.gov). Not yet FDA‑approved.
• CRISPR‑based editing: Early‑stage research aims to correct dominant gain‑of‑function mutations; still experimental.
• Retinal progenitor cell transplantation: Investigational; limited to academic centers.

Surgical / Procedural Options

• Low‑vision aids: Custom magnifiers, telescopic lenses, and electronic video magnifiers improve daily functioning.
• Implantable retinal prostheses (e.g., Argus II): Approved for advanced RP with residual inner retinal cells; may provide light perception and rudimentary shapes.
• Cataract surgery: Cataracts are common in RP; timely removal can enhance remaining vision.

Lifestyle & Supportive Measures

• Wear UV‑protective sunglasses (400 nm cutoff) to limit phototoxic damage.
• Adopt a diet rich in leafy greens, fatty fish, and antioxidants.
• Engage in regular, low‑impact exercise (e.g., walking, swimming) to support overall retinal health.
• Enroll in low‑vision rehabilitation programs for orientation, mobility training, and assistive technology education.

Living with X‑Linked Dominant Retinitis Pigmentosa

Patients and families often need a multidisciplinary approach.

• Regular ophthalmic follow‑up: Every 6–12 months, or more frequently if visual changes accelerate.
• Vision‑adaptation strategies:
  • Use high‑contrast labels on household items.
  • Organize spaces consistently to rely on memory over sight.
  • Prefer tactile or auditory cues (e.g., talking watches, Braille).
• Psychosocial support: Counseling, support groups (e.g., Foundation Fighting Blindness), and peer mentoring can reduce anxiety and depression associated with progressive loss.
• Driving considerations: Evaluate visual field requirements for licensing; many jurisdictions mandate a “restricted” or “non‑driving” status once field loss exceeds legal limits.
• Employment accommodations: Request ergonomic lighting, screen‑magnification software, and flexible screen‑reading tools.

Prevention

Because XLD‑RP is genetic, primary prevention (preventing the disease from occurring) is not possible. However, secondary preventive measures can mitigate the rate of deterioration:

• Genetic counseling for at‑risk couples.
• Avoid smoking and limit exposure to environmental toxins that exacerbate oxidative stress.
• Consistently use UV‑blocking eyewear outdoors.
• Maintain a balanced diet and consider supplementation under physician guidance.

Complications

If left unmanaged, XLD‑RP can lead to several vision‑related and systemic complications.

• Legal blindness: Defined as visual acuity ≤ 20/200 or visual field ≤ 20°; occurs in most affected males by the fourth to fifth decade.
• Cataract formation: RP patients develop posterior subcapsular cataracts earlier than the general population.
• Macular edema: Cystoid macular edema (CME) can cause sudden central vision decline; treatable with carbonic anhydrase inhibitors or intravitreal steroids.
• Psychological impact: Depression, anxiety, and social isolation are common; early mental‑health referral improves outcomes.
• Falls and injuries: Reduced peripheral vision increases risk of tripping; home safety modifications are advisable.

When to Seek Emergency Care

Preparedness tip: Keep a note of your ophthalmologist’s contact information and bring a copy of recent retinal imaging to the emergency department if possible.

For personalized advice, always consult a retinal specialist or genetic counselor. The information above reflects current knowledge as of 2026 and is intended for educational purposes only.

References:

1. Mayo Clinic. Retinitis Pigmentosa. https://www.mayoclinic.org
2. National Eye Institute. Inherited Retinal Diseases. https://www.nei.nih.gov
3. Orphanet. X‑linked dominant retinitis pigmentosa. https://www.orpha.net
4. World Health Organization. Blindness and Vision Impairment. https://www.who.int
5. Cleveland Clinic. Retinitis Pigmentosa: Symptoms, Diagnosis, and Treatment. https://my.clevelandclinic.org
6. ClinicalTrials.gov. Gene Therapy for RP2‑Related X‑Linked Retinitis Pigmentosa (NCT03840941). Retrieved 2026.